Development of pre-clinical murine models for fibrolamellar hepatocellular carcinoma
A. He, G. L. Coles, G. H. Hartmann, J. Arand, V. Le, B. Mauch, L. Xu, T. Nguyen, F. K. Hazard, J. Sage
Abstract
Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of cancer that affects primarily adolescents and young adults. FLC tumors are typically associated with an intrachromosomal deletion resulting in expression of a fusion protein between the chaperone DNAJ1B and the protein kinase PKA. FLC is challenging to study because of its rarity and limited pre-clinical models. Here we developed a novel transgenic mouse model of FLC. In this model, DNAJ1B-PKA expression in the liver of mouse embryos results in perinatal lethality associated with liver developmental defects, while DNAJ1B-PKA expression in the liver of adult mice initiates tumors resembling FLC at low penetrance. We sought to develop ex vivo cell models from these tumors but failed to establish long-term cell lines. New pre-clinical models of FLC will provide novel insights into the biology of this rare cancer and may help identify novel therapeutic strategies.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DNAJB1-PRKACA fusion induces liver inflammation in zebrafish model of Fibrolamellar Hepatocellular Carcinoma
S. de Oliveira, R. A. Houseright, … A. Huttenlocher·bioRxiv·Sep 25, 2019
- DNAJB1-PRKACA fusion kinase interacts with β-catenin and liver regenerative response to drive fibrolamellar hepatocellular carcinoma
E. R. Kastenhuber, G. Lalazar, … S. W. Lowe·Proceedings of the National Academy of SciencesPeer-reviewed·Nov 21, 2017
- Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
S. S. Schalm, E. O'Hearn, … K. P. Hoeflich·bioRxiv·Jan 31, 2022
- CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
M. Nukaya, C. Cafferty, … S. M. Ronnekleiv-Kelly·bioRxiv·Apr 22, 2023
- DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling
- DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma
R. K. Ma, P.-Y. Tsai, … P. Sethupathy·bioRxiv·Jun 2, 2023